October 20th 2025
Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.
October 19th 2025
Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.
Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.
At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.
Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.
Docetaxel/Darolutamide Plus ADT Limits High-Grade AEs in Metastatic HSPC
Updated safety findings may support the ARASAFE regimen as a potential standard of care in metastatic hormone-sensitive prostate cancer.
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
The novel PET imaging agent detected significantly more PSMA-positive prostate cancer lesions vs SOC in patients with low PSA levels.
Niraparib Combo Boosts rPFS in Metastatic HRR-Altered CSPC
Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.
EBRT Plus Focal Boost Sustains Biochemical DFS Benefit in Prostate Cancer
The 10-year biochemical DFS rate was 86% with EBRT plus focal boost vs 71% with standard EBRT in those with intermediate- and high-risk prostate cancer.
Salvage Nodal Radiation Shows Tolerability, Low Toxicity in Prostate Cancer
Imaging developments have made it possible to detect nodal recurrence at low PSA levels, which could help guide salvage approaches for prostate cancer.
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
RLT-based combinations, RLTs across genitourinary cancers, and RLTs in earlier lines of therapy are among the considerations for further research.
Two-Fraction SBRT Shows Acceptable Toxicity in Prostate Cancer Population
Grade 2 or higher genitourinary acute toxicity was observed in 27.3% of patients treated with 2 fractions of SBRT vs 29.2% of patients treated with 5 fractions.
SBRT Reduces Bowel Toxicity vs IMRT in Intermediate-Risk Prostate Cancer
SBRT achieved a 5-year DFS rate of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate-risk prostate cancer.
Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer
The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.
PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer
Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.
Carotuximab/Apalutamide Improves PFS in Previously Treated Metastatic CRPC
In an interim safety analysis, no dose-limiting toxicities, unexpected AEs, or grade 3/4 AEs were reported in 10 patients treated for metastatic CRPC.
FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer
Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.
HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC
Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.
FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer
The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.
INKmune Exhibits Favorable Safety in Metastatic CRPC
Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.
Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC
Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.
Carotuximab/Apalutamide Shows Tolerability in Metastatic CRPC
No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.
Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence
More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.
3 Things You Should Know About Advancing mCRPC Care: Targeted Sequencing, Epigenetics, and Emerging Strategies
Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.
Early Efficacy Seen With Gedatolisib-Based Therapies in Prostate/Breast Cancers
Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.
Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer
225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.
Radioligand Therapy Retreatment Shows Promise in Metastatic CRPC
Results from a retrospective study show that 177Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.
FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.
Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC
The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.
FDA OKs Darolutamide in Metastatic Castration-Sensitive Prostate Cancer
Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer
The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC
Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.
Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC
SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.
Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer
Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.
The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer
Decipher Prostate, Oncotype DX, and Prolaris are 3 gene expression testing options for patients with prostate cancers. Read as experts discuss them.